logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
2/25/2021 9:05:24 AM Aimmune Presents New Clinical Data From Pooled Safety Analysis In Patients Treated With PALFORZIA(r) For Up To 3.5 Years
7/2/2019 8:43:02 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
6/11/2019 12:59:04 PM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
6/6/2019 8:41:41 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $79 Price Target
3/19/2019 7:59:28 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY20 Rev. Estimate To 52.3 M From 78.6 M
3/19/2019 7:45:52 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q4 20 Rev. Estimate To 31.4 M From 42.8 M
3/19/2019 7:45:38 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q3 20 Rev. Estimate To 11.0 M From 19.6 M
3/19/2019 7:45:26 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q2 20 Rev. Estimate To 6.8 M From 11.7 M
3/19/2019 7:44:44 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q1 20 Rev. Estimate To 3.2 M From 4.5 M
3/19/2019 7:44:18 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY20 Estimate To -3.07 From -2.71
3/19/2019 7:44:05 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q4 20 Estimate To -0.53 From -0.37
3/19/2019 7:43:50 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q3 20 Estimate To -0.80 From -0.68
3/19/2019 7:43:35 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q2 20 Estimate To -0.85 From -0.78
3/19/2019 7:43:19 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) Q1 20 Estimate To -0.89 From -0.87
3/19/2019 7:43:03 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -3.66 From -3.63
3/19/2019 7:42:49 AM Wedbush Is Cutting Aimmune Therapeutics Inc. (AIMT) Q4 19 Estimate To -0.95 From -0.92
3/19/2019 7:42:02 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $76 Down From $80 Price Target
2/5/2019 7:58:06 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $80 Price Target
8/9/2018 9:05:53 AM Wedbush Is Raising Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -2.72 From -2.73
8/9/2018 9:05:38 AM Wedbush Is Lowering Aimmune Therapeutics Inc. (AIMT) FY18 Estimate To -3.35 From -3.26